LeMaitre Vascular, Inc.

lemaitre.com

What Do They Do?

Sells vascular devices and provides human-tissue cryopreservation services for vascular surgeons and other surgical specialists treating vascular and cardiovascular disease.

How Do They Make Money?

Hospitals and, to a lesser extent, international distributors buy disposable and implantable vascular devices; the company also processes and preserves human tissue. Product sales are tied to shipment or delivery (or use of consigned stock), and customers typically pay after orders are fulfilled.

FY2025 revenue

Who Are Their Customers?

Hospitals buy directly through the company’s sales force in its direct markets; buyers in other countries are served through distributors.

Customers above 10% of revenue, FY2025

of revenue from one customer

Do Revenues Turn Into Profits?

Yes. It kept 23 cents of every revenue dollar as net income in FY2025 and turned 30 cents into free cash flow.

Operating income, FY2025

27% of revenue

▲ +30% vs FY2024 ($52.3M, 24%)

Net income, FY2025

23% of revenue

▲ +31% vs FY2024 ($44M, 20%)

Free cash flow, FY2025

30% of revenue

▲ +100% vs FY2024 ($37.2M, 17%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +10%; vs $64.2M in Q2 FY2025
Net income: ▲ +24%; vs $13.8M in Q2 FY2025

Aug 4, 2026 Issued quarterly results and future-period financial guidance The release gave sales, operating income and earnings-per-share guidance for upcoming quarters and the full year.

Growing. Revenue grew 62% in 4 years, from $154.4M in FY2021 to $249.6M in FY2025, about 13% a year.

PeriVu discontinued The older report describes the PeriVu disposable angioscope; the latest report says the company decided to wind down that product line.

Who Do They Compete With?

Competes with Abbott, Baxter, Artivion, Becton Dickinson, Edwards Lifesciences, Getinge, LifeNet Health, Terumo, and W. L. Gore

Comments